An T2 Biosystems Inc. (TTOO) Chief Financial Officer Buys 10000.0 Shares

SNOW Stock
SNOW Stock

T2 Biosystems Inc. (NASDAQ:TTOO) finished Thursday with a subtraction of -$0.01 to close at $0.09, a downside of -11.83 percent. An average of 16,793,461 shares of common stock have been traded in the last five days. There was a fall of -$0.0270 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 22,093,600 shares traded, while the 50-day average volume stands at 49,593,434.

TTOO stock has decreased by -28.25% in the last month. The company shares reached their 1-month lowest point of $0.0890 on 09/22/22. With the stock rallying to its 52-week high on 04/01/22, shares of the company touched a low of $0.10 and a high of $1.08 in 52 weeks. It has reached a new high 2 times so far this year and lost -82.68% or -$0.4268 in price. In spite of this, the price is down -91.72% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Insider Transactions

260 days have passed since T2 Biosystems Inc. (TTOO) last reported insider trading activity. Ahuja Aparna, who is Chief Medical Officer, most recently acquired $61,988 shares at $0.48 per share on Jan 06.

Valuation Metrics

T2 Biosystems Inc. (TTOO) stock’s beta is 0.48. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.21.

Financial Health

The quick ratio of T2 Biosystems Inc. for the three months ended June 29 was 1.40, and the current ratio was 1.90, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $7.36 million compared to revenue of $28.06 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, T2 Biosystems Inc.’s return on assets was -110.60%.

Earnings Surprise

For the three-month period that ended June 29, T2 Biosystems Inc. had $48.71 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$18.03 million in the quarter, while revenues of -$16.5 million were grew 30.78%. The analyst consensus anticipated T2 Biosystems Inc.’s latest quarter earnings to come in at -$0.09 per share, but it turned out to be -$0.1, a -11.10% surprise. For the quarter, EBITDA amounted to -$14.47 million. Shareholders own equity worth $352.54 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at T2 Biosystems Inc. (TTOO) price momentum. RSI 9-day as of the close on 22 September was 21.18%, suggesting the stock is oversold, with historical volatility in this time frame at 64.35%.

As of today, TTOO’s price is $0.1009 -23.20% or -$0.0270 from its 5-day moving average. TTOO is currently trading -30.16% lower than its 20-day SMA and -75.84% lower than its 100-day SMA. However, the stock’s current price level is -40.00% below the SMA50 and -83.70% below the SMA200.

The stochastic %K and %D were 4.47% and 8.78%, respectively, and the average true range (ATR) was 0.0114. With the 14-day stochastic at 0.98% and the average true range at 0.0132, the RSI (14) stands at 29.74%. The stock has reached -0.0108 on the 9-day MACD Oscillator while the 14-day reading was at -0.0122.

Analyst Ratings

Alliance Global Partners downgraded T2 Biosystems Inc. (NASDAQ: TTOO) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for T2 Biosystems Inc. (TTOO) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TTOO, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is TTOO’s price target for the next 12 months?

Analysts predict a range of price targets between $0.14 and $0.25, with a median target of $0.20. Taking a look at these predictions, the average price target given by analysts for T2 Biosystems Inc. (TTOO) stock is $0.20.


Please enter your comment!
Please enter your name here